Quantcast

Latest Trastuzumab Stories

2011-12-08 12:55:30

Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved progression-free survival in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Luca Gianni, M.D., director of medical oncology at the San Raffaele Cancer Center in Milano, Italy, presented results from AVEREL, a randomized, phase 3 trial, at the 2011...

2011-12-08 12:53:09

Adding pertuzumab to a combination of trastuzumab and docetaxel chemotherapy extended progression-free survival by a median of 6.1 months in patients with metastatic HER2-positive breast cancer compared with patients who received the combination therapy with placebo. Researchers conducted an international phase 3, double-blind, randomized trial, known as CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab), in which they randomly assigned 808 patients to receive trastuzumab and...

2011-12-07 14:36:01

One study presented at the meeting, which is being held in Budapest, Hungary, 7 to 10 December, reports on an initiative using echocardiography to document early warning signs of adverse effects from trastuzumab (Herceptin ®)´, while the other uses echocardiography to evaluate the protective role of ACE inhibitors and statins on the hearts of cancer patients². "These studies open the way for the early identification of myocardial damage at the subclinical level, thereby...

2011-12-01 19:03:26

Sequencing points to treatment protocols, results in patient benefit Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin® (trastuzumab). To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010, and the first results will be presented during the 2011 CTRC-AACR San Antonio...

2011-11-04 12:00:00

Current testing protocols for HER2 amplification may exclude thousands of patients who actually have HER2 gene amplification, delaying or preventing them from receiving potentially life-saving treatment. A new laboratory testing protocol can more accurately identify an important group of breast cancer patients who are most likely to benefit from a âœtargeted therapyâ shown to dramatically improve survival. This recent discovery by PhenoPath Laboratories...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related